Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting

Reuters

2025/10/14

Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting

Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575291410"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575291410\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575291410?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575291410","market":"fut","top_or_hot":-1,"title":"Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7g94kd:1","article_id":"2575291410","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575291410","pubTimestamp":1760439649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology  annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant , with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking  will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","GKOS":"Glaukos Corp","BK4548":"巴美列捷福持仓","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"Glaukos在2025年AAO年会上重点介绍iDose TR和角膜交联的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":0.9},"content_text":"Glaukos Highlights New Clinical Data on iDose TR and Corneal Cross-Linking at 2025 AAO Annual Meeting\n    \n\n        Glaukos Corporation has announced that its technologies will be featured in various scientific programming at the upcoming 2025 American Academy of Ophthalmology (AAO) annual meeting, scheduled for October 18-20, 2025, in Orlando, Florida. Key clinical studies to be highlighted include the Travoprost Intracameral Implant (iDose® TR), with data on its ability to significantly reduce the need for topical intraocular pressure-lowering medications for up to 36 months, and its use in conjunction with cataract surgery with outcomes reported at 12 months. Additionally, results from a Phase 3, multicenter, randomized, sham/placebo-controlled trial demonstrating the safety and efficacy of epithelium-on corneal cross-linking (CXL) will be presented. These study findings will be presented at the AAO meeting, and detailed abstract information is available on the AAO website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014079380) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}